Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 7/20 | 0.38 |
| ▸ | MMP1 | P03956 | 4/20 | 0.38 |
| ▸ | MMP3 | P08254 | 3/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.38 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | AREG | P15514 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11561060 | 0.90 | GHSR (0.43) | POLBFAAHP2RX7MTNR1AMTNR1B | |
| SCHEMBL11560899 | 0.90 | GHSR (0.43) | POLBFAAHP2RX7MTNR1AMTNR1B | |
| SCHEMBL11559327 | 0.80 | FAAH (0.38) | GRM1FAAHP2RX7MTNR1AMTNR1B | |
| SCHEMBL11582233 | 0.78 | UGCG (0.40) | POLBLMNAMTNR1AMTNR1B | |
| SCHEMBL11663985 | 0.77 | AKR1C3 (0.44) | POLBLMNAMEN1KMT2A | |
| SCHEMBL11665562 | 0.77 | AKR1C3 (0.44) | POLBLMNAMEN1KMT2A | |
| SCHEMBL20684880 | 0.76 | AKR1C3 (0.46) | POLBLMNA | |
| SCHEMBL1131625 | 0.75 | — | — | |
| SCHEMBL11544068 | 0.74 | AKR1C3 (0.55) | POLBLMNAMEN1KMT2APDE4A | |
| SCHEMBL14022821 | 0.73 | MTNR1A (0.47) | GRM1FAAHMTNR1AMTNR1BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063240-B2 | Prostaglandin E1 and E2 analogs for the treatment of various medical conditions | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2220057-A2 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | Cayman Chemical Company (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090221654-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | CAYMAN CHEMICAL COMPANY (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009065070-A2 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | CAYMAN CHEMICAL COMPANY (US) | 2009-05-22 | — | — | WO | disclosed |
| US-6649655-B2 | Such as (5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanonr-5, 13-prostadienoic acid isopropyl ester; prostaglandins for treatment of ocular hyperemia, macular edema, iris hyperpigmentation/melanogenesis | ALCON MANUFACTURING, LTD. | 2003-11-18 | — | — | US | disclosed |
| US-20030083375-A1 | 11Beta-fluoro 15beta-hydroxy PGF2alpha analogs as FP receptor antagonists | ALCON RESEARCH, LTD. | 2003-05-01 | — | — | US | disclosed |
| US-6441033-B1 | PROSTAGLANDIN RECEPTOR ANTAGONISTS | ALCON MANUFACTURING, LTD. | 2002-08-27 | — | — | US | disclosed |
| US-6353000-B1 | INTRAOCULAR HYPERTENSION TREATMENT | ALCON LABORATORIES, INC. | 2002-03-05 | — | — | US | disclosed |
| US-6211226-B1 | 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension | ALCON LABORATORIES, INC. | 2001-04-03 | — | — | US | disclosed |
| WO-1998020880-A2 | 11-HALO PROSTAGLANDINS FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | ALCON LABORATORIES, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| US-4152527-A | 15-Substituted-ω-pentanorprostaglandins | PFIZER INC. (US) | 1979-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083375-A1 | 11Beta-fluoro 15beta-hydroxy PGF2alpha analogs as FP receptor antagonists | PTGER1, PTGIR, PTGFR | POLB 1306/4885LMNA 3576/4885MMP9 1529/4885 |
| US-20090221654-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | PTGER1, PTGER4, PTGER2 | POLB 2102/4885LMNA 1107/4885MMP9 2436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.